Operates as a biopharmaceutical company with three reporting segments. Biosimilars is the largest at 60.2% of segment revenue (₹10,431.2 crore in FY26) and makes biologic copies of approved drugs — insulins, ustekinumab (sold as Yesintek), adalimumab, aflibercept (Yesafili) and denosumab — selling to global markets, with 12 biosimilar products commercialized worldwide. The CRDMO segment (21.6%, ₹3,738.7 crore) is the Syngene contract research, development and manufacturing business that serves external pharma clients. Generics (18.3%, ₹3,168.1 crore) sells small-molecule generic finished dosages and APIs, including a legacy lenalidomide contribution. Cost structure is dominated by materials at 31.2% of revenue and employees at 20.7%, with depreciation at 11.6% and capex at 10.6% of revenue, reflecting the asset-heavy biologics manufacturing base. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Biosimilars (60%), CRDMO (22%), Generics (18%). Asset-heavy biopharmaceutical manufacturer spanning biologics, contract services and small-molecule generics, with high depreciation and ongoing capex
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 8,184 | 11,174 | 14,756 | 15,262 | 16,927 |
| EBITDA (ex other income) | 1,859 | 2,220 | 3,287 | 3,263 | 3,052 |
| margin % | 22.7 | 19.9 | 22.3 | 21.4 | 18.0 |
| Owners' profit | 648 | 463 | 1,023 | 1,013 | 386 |
| EPS, as reported (₹) | 5.44 | 3.88 | 8.55 | 8.46 | 2.82 |
| ROE % · ROCE % | 8.1 · 7.6 | 2.9 · 3.4 | 5.1 · 6.3 | 5.2 · 6.3 | 1.0 · 2.9 |
| Debt / equity (x) | 0.52 | 0.79 | 0.62 | 0.64 | 0.40 |
| Cash from operations | 1,177 | 1,853 | 2,954 | 4,061 | 1,994 |
| Capex | (1,698) | (1,596) | (1,681) | (2,137) | (1,798) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3,590 | 3,821 | 4,417 | 3,942 | 4,296 | 4,173 | 4,517 | 4,336 |
| Profit before tax | 98 | 156 | 487 | 97 | 171 | (68) | 248 | 128 |
| Net profit | 27 | 81 | 459 | 89 | 133 | (52) | 199 | 137 |
| EPS (₹) | (0.13) | 0.21 | 2.88 | 0.26 | 0.66 | 1.08 | 0.79 | 0.87 |
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Generics | 3,168 | 18.3 |
| Biosimilars | 10,431 | 60.2 |
| CRDMO | 3,739 | 21.6 |
| Total, before eliminations | 17,338 | 100.0 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 9 Sept 2026 · Biocon informs exchanges about final dividend remittance for FY2025-26 | corporate actions | high | — | — |
| 8 Sept 2026 · Schedule of meeting with analysts and institutional investors | board shareholder meetings | low | — | — |
| 8 Sept 2026 · Biocon wins 10-year Brazil supply deal for breast cancer drug | business updates | high | — | — |
| 31 Aug 2026 · Biocon to meet analysts at Nomura Asian Credit Corporate Day 2026 | board shareholder meetings | low | — | — |
| 28 Aug 2026 · Biocon remits final dividend of Re 0.50/share for FY 2025-26 | corporate actions | high | — | — |
| 26 Aug 2026 · Mylan Inc exits Biocon fully, revised disclosure corrects holding to Nil | ownership changes | high | — | — |
| 25 Aug 2026 · Biocon Biologics gets Japan approval for Pegfilgrastim biosimilar | business updates | high | — | — |
| 18 Aug 2026 · Biocon gets U.S. FDA nod for Yesintek autoinjector format | business updates | high | — | — |
| 11 Aug 2026 · Biocon to attend Motilal Oswal Global Investor Conference on Aug 17 | board shareholder meetings | low | — | — |
| 11 Aug 2026 · Biocon Q1 FY27 earnings call transcript filed | investor communications | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| DIVI S LABORATORIES LTD |
| 2,47,033 |
| 84.6 |
| 14.74 |
| 63.7 |
| 15.3 |
| 18.8 |
| 8.7 |
| 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 114.9 | 28.9 | 163 of 169 | 4% |
| P/B | 1.7 | 3.3 | 45 of 163 | 73% |
| ROCE | 0.9 | 10.8 | 149 of 183 | 19% |
| ROE | 1.0 | 10.4 | 142 of 171 | 17% |
| Debt / Equity | 0.4 | 0.1 | 131 of 171 | 24% |
| EBITDA margin | 20.5 | 17.5 | 74 of 165 | 56% |
| Revenue growth | 10.0 | 16.3 | 94 of 161 | 42% |
| Profit growth | 53.4 | 30.9 | 63 of 158 | 61% |
| Market cap | 63664 | 839 | 12 of 182 | 94% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
